Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Receptor Life Sciences.

    Client Virtual Booth

    RECEPTOR LIFE SCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Receptor Life Sciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1200 Fifth Avenue, Suite 1400 Seattle, Washington 98101
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.receptorlife.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid E...

    Details:

    RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of psychiatric and neurological disorders.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Neurology Product Name: RLS103

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Begins Dosing with RLS103 in PIb/IIa Study in Anxiety

    Details:

    RLS103, a dry powder inhaled cannabidiol (CBD), uses an inhalation formulation technology coupled with a breath-powered device, both currently used in two FDA-approved products.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: RLS103

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 29, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Secures $9.7 Million Financing to Advance RLS103 (Inhaled Dry Powder CBD) into Clinical Trials

    Details:

    RLS will use proceeds from financing to advance RLS103 through proof-of-concept clinical safety and efficacy studies in treatment of psychiatric and neurological disorders. RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: RLS103

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Granite Point Capital

    Deal Size: $9.7 million Upfront Cash: Undisclosed

    Deal Type: Financing April 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and...

    Details:

    The RLS103 inhalation powder contains synthetic CBD and FDKP, an FDA-approved inhalation excipient. In an initial proof-of-concept pharmacokinetic clinical study, RLS103 provided immediate CBD absorption with peak concentration less than 4 minutes after inhalation.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: RLS103

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum Disorder

    Details:

    RLS102 is a first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder that uses an FDA-approved drug delivery technology.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Neurology Product Name: RLS102

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Receptor Life Sciences Receives FDA Guidance for Development of RLS 103, Designed for the Treatment of Acute Panic Attack

    Details:

    Receptor Life Sciences has completed a pre-investigational new drug meeting with the U.S. FDA. The meeting resulted in clear guidance on the regulatory requirements for the development and approval of RLS103 under section 505(b)(2).


    Lead Product(s): Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: RLS 103

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 17, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search